Skip to main content Accessibility help
×
Home

Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice

  • Honggang Wang (a1), Jianning Dong (a1), Lugen Zuo (a1), Jianhui Liu (a1), Weiming Zhu (a1), Yi Li (a1), Lili Gu (a1), Jie Zhao (a1), Liang Zhang (a1), Jianfeng Gong (a1), Wei Zhang (a1), Ning Li (a1) and Jieshou Li (a1)...

Abstract

Approximately 50 % of patients with inflammatory bowel disease (IBD) suffer from anaemia, with Fe deficiency being the most common cause. CD52 monoclonal antibody (mAb) targets the cell surface CD52 and is effective in depleting lymphocytes through cytolytic effects in vivo. The aim of the present study was to investigate the therapeutic effect of anti-mouse CD52 mAb on Fe-deficient anaemia in IBD. IL-10 knockout mice (IL-10− / −) of 12 weeks with established colitis were treated with anti-mouse CD52 mAb once per week for 2 weeks. Severity of colitis, blood T lymphocytes, blood Hb, haematocrit, plasma erythropoietin (EPO), serum Fe concentration, transferrin saturation, splenic Fe stores, expression of liver hepcidin mRNA, Western blotting of the phosphorylated form of Smad1/5/8 and total Smad1 were measured at the end of the experiment. IL-10− / − mice treated with CD52 mAb showed a reduction in the percentage of CD4+ and CD4+CD45+ T cells in blood and weight loss typically associated with colonic inflammation, serum levels of EPO, the expression of liver hepcidin mRNA and total Smad1 protein, while they showed an increase in Hb concentrations, haematocrit, levels of serum Fe, transferrin saturation and splenic Fe stores. The present results indicated that anti-CD52 therapy may ameliorate Fe-deficient anaemia by reducing colonic inflammation. These findings may open novel horizons in the treatment of patients with IBD by resetting of immunological homeostasis in the gut by depleting the activated T cells in the gut mucosa.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: W. Zhu, email zhuwiming@126.com

References

Hide All
1 Ordas, I, Eckmann, L, Talamini, M, et al. (2012) Ulcerative colitis. Lancet 380, 16061619.
2 Tyagi, A, Kumar, U, Reddy, S, et al. (2012) Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with alpha-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr 108, 16121622.
3 Singh, UP, Singh, NP, Singh, B, et al. (2012) Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10( − / − ) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258, 256267.
4 Goodhand, JR, Kamperidis, N, Rao, A, et al. (2012) Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 18, 513519.
5 Carter, PR, Watts, MN, Kosloski-Davidson, M, et al. (2013) Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis. Inflamm Bowel Dis 19, 12601265.
6 Lomer, MC, Cook, WB, Jan-Mohamed, HJ, et al. (2012) Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr 107, 18061811.
7 Stein, J, Hartmann, F & Dignass, AU (2010) Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 7, 599610.
8 Berg, DJ, Zhang, J, Weinstock, JV, et al. (2002) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123, 15271542.
9 Ouyang, W, Rutz, S, Crellin, NK, et al. (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29, 71109.
10 Kuhn, R, Lohler, J, Rennick, D, et al. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263274.
11 Kaser, A, Zeissig, S & Blumberg, RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28, 573621.
12 Hentze, MW, Muckenthaler, MU, Galy, B, et al. (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142, 2438.
13 Oustamanolakis, P, Koutroubakis, IE, Messaritakis, I, et al. (2011) Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol 23, 262268.
14 Wang, L, Trebicka, E, Fu, Y, et al. (2012) The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 18, 112119.
15 Babitt, JL, Huang, FW, Xia, Y, et al. (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117, 19331939.
16 Maloy, KJ & Powrie, F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298306.
17 MacDonald, TT, Biancheri, P, Sarra, M, et al. (2012) What's the next best cytokine target in IBD. Inflamm Bowel Dis 18, 21802189.
18 Jones, JL, Phuah, CL, Cox, AL, et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119, 20522061.
19 Rao, SP, Sancho, J, Campos-Rivera, J, et al. (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLOS ONE 7, e39416.
20 Qu, L, Li, Q, Jiang, H, et al. (2009) Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes. Transplantation 88, 766772.
21 Coles, AJ, Twyman, CL, Arnold, DL, et al. (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 18291839.
22 Scheinberg, P, Nunez, O, Weinstein, B, et al. (2012) Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 119, 345354.
23 Zhu, WM, Li, Y, Yu, C, et al. (2011) Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice. Inflamm Bowel Dis 17, E72E73.
24 Berg, DJ, Davidson, N, Kuhn, R, et al. (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98, 10101020.
25 Li, Y, Yu, C, Zhu, WM, et al. (2010) Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol 47, 24672474.
26 Cuzzocrea, S, Mazzon, E, Di, PR, et al. (2004) Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther 311, 12721280.
27 Katsanos, KH, Tatsioni, A, Natsi, D, et al. (2012) Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: a 15-year single center experience. J Crohns Colitis 6, 5661.
28 Baumgart, DC & Sandborn, WJ (2012) Crohn's disease. Lancet 380, 15901605.
29 Liu, B, Tonkonogy, SL & Sartor, RB (2011) Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology 141, 653662, 662.e1–662.e4.
30 Gasche, C, Reinisch, W, Lochs, H, et al. (1994) Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 39, 19301934.
31 Nairz, M, Schroll, A, Moschen, AR, et al. (2011) Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 34, 6174.
32 Nairz, M, Sonnweber, T, Schroll, A, et al. (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14, 238246.
33 Nemeth, E, Tuttle, MS, Powelson, J, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 20902093.
34 Zhang, DL, Senecal, T, Ghosh, MC, et al. (2011) Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood 118, 28682877.
35 Qiao, B, Sugianto, P, Fung, E, et al. (2012) Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab 15, 918924.
36 Wang, L, Harrington, L, Trebicka, E, et al. (2009) Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 119, 33223328.
37 Shanmugam, NK, Ellenbogen, S, Trebicka, E, et al. (2012) Tumor necrosis factor alpha inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis. PLOS ONE 7, e38136.
38 Zhao, N, Zhang, AS & Enns, CA (2013) Iron regulation by hepcidin. J Clin Invest 123, 23372343.
39 Pietrangelo, A, Dierssen, U, Valli, L, et al. (2007) STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo . Gastroenterology 132, 294300.
40 Song, SN, Tomosugi, N, Kawabata, H, et al. (2010) Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116, 36273634.
41 Andriopoulos, B Jr, Corradini, E, Xia, Y, et al. (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41, 482487.
42 Babitt, JL, Huang, FW, Wrighting, DM, et al. (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38, 531539.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed